JHVEPhoto/iStock Editorial via Getty Images I believe that the financials of any company are always only a derivative of its underlying products. To understand the future of financial flows of an asset, one must first understand the future of its base product. Today, looking at the chart of Adobe ( ADBE ), we see a classic paradox: the capitalization fell to $100 billion, and the forward multiple ...
JHVEPhoto/iStock Editorial via Getty Images I believe that the financials of any company are always only a derivative of its underlying products. To understand the future of financial flows of an asset, one must first understand the future of its base product. Today, looking at the chart of Adobe ( ADBE ), we see a classic paradox: the capitalization fell to $100 billion, and the forward multiple P/E compressed to 10.4x–12x (against an average of 44x for the last 10 years). Against this backdrop, many analysts are issuing a consensus ' Buy ' rating and " Strong Buy, " arguing this by an extreme cheapness. Frankly, almost no one is calling to sell. However, the market does not value the company cheaply for no reason. Adobe's problem is not about market conditions but rather that in perspective its ecosystem can rapidly lose its uniqueness under the pressure of generative artificial intelligence. But instead of throwing all resources into defending its technological edge, the leadership of the company, it seems, chooses the path of financial engineering, planning to funnel profits into massive share buybacks of $25 billion . Short-term support of the share price here and now will be, figuratively speaking, diverting critical capital away from vital research and development (R&D). Because this money is not being invested into technologies. The conclusion, perhaps, is harsh: without a competitive product there will be neither revenue nor margins, meaning that in a few years this asset risks being fundamentally depreciated. Erosion of product and how AI destroys the effect of scale of Adobe Historically, Adobe offered a magnificent product. As of 2021, the ecosystem of Photoshop, Premiere, and Illustrator was almost without alternatives. The company sold a complex but necessary set of instruments—the " brushes and paints " of the digital era. The user paid for the very process of work. But the era of AI completely changes this paradigm. It assumes that in the future arti...
Palmer Square Capital BDC press release ( PSBD ): Q1 net investment income of $11M or $0.35 per share for the first quarter of 2026, compared to $12.9M or $0.40 per share for the prior year period. Net asset value of $13.30 per share as of March 31, 2026, compared to $14.85 per share as of December 31, 2025. Total net realized and unrealized losses of $48.3M for the first quarter of 2026, compared...
Palmer Square Capital BDC press release ( PSBD ): Q1 net investment income of $11M or $0.35 per share for the first quarter of 2026, compared to $12.9M or $0.40 per share for the prior year period. Net asset value of $13.30 per share as of March 31, 2026, compared to $14.85 per share as of December 31, 2025. Total net realized and unrealized losses of $48.3M for the first quarter of 2026, compared to losses of $21.3M for the first quarter of 2025. More on Palmer Square Capital BDC Palmer Square Capital BDC Inc. (PSBD) Q4 2025 Earnings Call Transcript Palmer Square Capital BDC Inc. 2025 Q4 - Results - Earnings Call Presentation Palmer Square Capital BDC: Trading At A Massive Discount For A Reason Palmer Square Capital BDC signals continued high yield and portfolio diversification amid volatile credit markets Palmer Square Capital BDC GAAP EPS of $1.66
(RTTNews) - Wednesday, Madrigal Pharmaceuticals, Inc. (MDGL) announced its first-quarter financial results, reporting a net loss of $94.4 million, or $3.25 a share, compared to $73.2 million, or $2.61 a share, in the previous year.
(RTTNews) - Wednesday, Madrigal Pharmaceuticals, Inc. (MDGL) announced its first-quarter financial results, reporting a net loss of $94.4 million, or $3.25 a share, compared to $73.2 million, or $2.61 a share, in the previous year.
*Other Operating Data Consensus Source: Bloomberg More on Disney Disney: Take A 'Wait And See' Approach Ahead Of Earnings Disney And Netflix: Both Names Look Attractive Disney: Succession Plan Underway Disney rallies after posting growth across all segments in FQ2 Disney Non-GAAP EPS of $1.57 beats by $0.07, revenue of $25.17B beats by $320M
*Other Operating Data Consensus Source: Bloomberg More on Disney Disney: Take A 'Wait And See' Approach Ahead Of Earnings Disney And Netflix: Both Names Look Attractive Disney: Succession Plan Underway Disney rallies after posting growth across all segments in FQ2 Disney Non-GAAP EPS of $1.57 beats by $0.07, revenue of $25.17B beats by $320M
S&P 500 Index futures rise 0.9% as of 7:50 a.m. in New York after a report that the US believes it’s close to an agreement with Iran to end the war. Nasdaq 100 futures are rise 1.5% Dow Jones Industrial Average futures are up 1.2% The MSCI World Index is up 0.6% Here are some of the biggest US movers before the bell: Magnificent Seven: Alphabet (GOOGL) climbs 1.6% after the Information reported th...
S&P 500 Index futures rise 0.9% as of 7:50 a.m. in New York after a report that the US believes it’s close to an agreement with Iran to end the war. Nasdaq 100 futures are rise 1.5% Dow Jones Industrial Average futures are up 1.2% The MSCI World Index is up 0.6% Here are some of the biggest US movers before the bell: Magnificent Seven: Alphabet (GOOGL) climbs 1.6% after the Information reported that AI startup Anthropic plans to spend about $200 billion with Google over five years. Amazon (AMZN) +1%, Apple (AAPL) -0.5%, Nvidia (NVDA) +2.5%, Meta Platforms (META) +0.5%, Microsoft (MSFT) +0.1, Tesla (TSLA) +0.6% Miners, cruise operators and airline companies gain, while energy and fertilizer stocks fall, after a report on the US and Iran nearing a one-page memorandum of understanding to end the war. Semiconductor, power equipment and data center stocks rally after solid results from Advanced Micro Devices and Super Micro — in a sign of robust end-to-end artificial intelligence-related demand. Advanced Micro Devices (AMD) rallies 19% after the chipmaker gave an outlook that is stronger than expected, a sign of robust AI-related demand. Alphatec Holdings (ATEC) sinks 16% after the medical device company posted sales for the first quarter that disappointed Wall Street. TD Cowen calls the report a “tough start to 2026.” Apollo Global (APO) rises 3% after the alternative asset manager eclipsed $1 trillion of assets under management on record first-quarter inflows and reported earnings that beat Wall Street estimates. Compass Inc. (COMP) gains 31% after the real estate brokerage platform reported first-quarter revenue that beat average analyst estimates. The firm’s second-quarter revenue forecast is ahead of consensus. CVS Health (CVS) rises 5% after the health insurer boosted its adjusted earnings per share guidance for the full year. The firm also posted adjusted profit and comparable sales for the first quarter that topped the average analyst estimate. Geo Group (GEO) ga...
Earnings Call Insights: Huron Consulting Group (HURN) Q1 2026 Management View "Revenues before reimbursable expenses, or RBR, increased 12% in the first quarter of 2026 compared to the first quarter of 2025, driven by growth across the Healthcare, Education and Commercial segments, including record RBR performance in health care." (President, CEO & Director C. Hussey) "Encouraged by the strong sta...
Earnings Call Insights: Huron Consulting Group (HURN) Q1 2026 Management View "Revenues before reimbursable expenses, or RBR, increased 12% in the first quarter of 2026 compared to the first quarter of 2025, driven by growth across the Healthcare, Education and Commercial segments, including record RBR performance in health care." (President, CEO & Director C. Hussey) "Encouraged by the strong start to the year and strength of our pipeline and backlog, we're affirming our annual RBR and margin guidance." (President, CEO & Director Hussey) "In the Healthcare segment, first quarter RBR grew 14% over the prior year quarter" and "organic growth for the Healthcare segment was 10%" excluding acquisitions, alongside comments that providers face "rising operational costs and labor shortages" and that "developing and executing an AI strategy" is increasingly important to clients. (President, CEO & Director Hussey) "In the first quarter of 2026, Education segment RBR grew 4%" as management described "a significant decline in international students" and said institutions are prioritizing solutions delivering "near-term financial improvement" while "increasingly leveraging AI." (President, CEO & Director Hussey) "In the Commercial segment, first quarter RBR grew 22%" and "excluding the impact of acquisitions, RBR in Q1 2026 grew 8% organically" as the company said investments have "delivered more durable growth in the Commercial business in recent quarters." (President, CEO & Director Hussey) "First quarter of 2026 produced RBR of $443.7 million" and "adjusted non-GAAP EPS" was "$1.73 per diluted share" while "our expectation for a full year effective tax rate between 28% and 30% remains unchanged." (Executive VP, CFO & Treasurer John Kelly) Outlook "We are affirming our 2026 guidance" for "RBR in the range of $1.78 billion to $1.86 billion, adjusted EBITDA in the range of 14.5% to 15% of RBR and adjusted non-GAAP EPS in the range of $8.35 to $9.15." (Executive VP, CFO & Treasu...
Earnings Call Insights: Rigel Pharmaceuticals (RIGL) Q1 2026 Management View “In the first quarter of 2026, we generated net product sales of just under $55 million, representing a 26% growth compared to the first quarter of 2025.” (President, CEO & Director Raul Rodriguez) “As expected, the first quarter was impacted by seasonal factors, including reimbursement dynamics...” and “we expect to retu...
Earnings Call Insights: Rigel Pharmaceuticals (RIGL) Q1 2026 Management View “In the first quarter of 2026, we generated net product sales of just under $55 million, representing a 26% growth compared to the first quarter of 2025.” (President, CEO & Director Raul Rodriguez) “As expected, the first quarter was impacted by seasonal factors, including reimbursement dynamics...” and “we expect to return to sequential growth starting in the second quarter.” (President, CEO & Director Rodriguez) “We are maintaining our 2026 revenue guidance for total revenues of $275 million to $290 million, including net product sales of $255 million to $265 million.” (President, CEO & Director Rodriguez) “We also remain on track to achieve net income profitability in 2026.” (President, CEO & Director Rodriguez) “We are actively evaluating late-stage in-license or acquisition opportunities that would support potential launches between 2026 and 2028.” (President, CEO & Director Rodriguez) “We generated $54.9 million in U.S. net product sales” and “we observed improving demand in March, which showed stronger volume across our product portfolio.” (Executive VP & Chief Commercial Officer David Santos) “We reported net income of $8.7 million for the first quarter...” and “we ended the quarter with cash, cash equivalents and short-term investments of $146.7 million...” (Executive VP & CFO Dean Schorno) Outlook “We are maintaining our 2026 revenue guidance for total revenues of $275 million to $290 million, including net product sales of $255 million to $265 million.” (President, CEO & Director Raul Rodriguez) “We continue to expect total revenue in the range of approximately $275 million to $290 million... approximately $255 million to $265 million in net product sales and $20 million to $25 million of contract revenues.” (Executive VP & CFO Dean Schorno) Compared with Q4 2025, management repeated the same 2026 ranges: “total revenue... $275 million to $290 million... net product sales... $255...